Marpai Inc Stock Price, News & Analysis

Marpai (OTCQX: MRAI) announced a private placement on Oct 6, 2025 raising approximately $200,000 from HillCour Investment Fund, an entity controlled by CEO Damien Lamendola. The purchase comprised 147,058 shares at $1.36 per share. The company said net proceeds will be used for general corporate purposes, including accelerating product deployment, enhancing its technology platform, and deepening market penetration among self-funded employer groups. Marpai reported a total of $1.7 million raised in Q3 2025. The placement relied on exemptions under Section 4(a)(2) and Regulation D and is not an offer to sell publicly.

Marpai (OTCQX: MRAI), a healthcare technology and TPA services provider, reported significant improvements in its Q2 2025 financial results, marking substantial progress in its turnaround strategy. The company achieved a 70% reduction in operating expenses, saving $9.9 million, and reduced its operating loss by 71% to $3.6 million.

Net loss decreased by 66% to $4.4 million, with net loss per share improving by $0.95. However, net revenues declined by $2.5 million to $4.7 million compared to the same quarter last year. CEO Damien Lamendola expressed confidence in achieving profitability by Q1 2026, citing a strong pipeline of new business and planned infrastructure investments in Q3 2025.

Marpai (OTCQX: MRAI), a healthcare technology and Third-Party Administration (TPA) services provider, has scheduled its Q2 2025 earnings conference call for August 14, 2025, at 8:30 a.m. ET. The company will release its second quarter 2025 financial results after market close on August 13.

Investors can access the call via phone at 1-800-836-8184 (toll-free) or 1-646-357-8785, and through webcast at https://app.webinar.net/pD32GbLd5Mx. A replay will be available for one week until August 21, 2025, using replay code 02046.

Marpai (OTCQX: MRAI) has announced the comprehensive relaunch of MarpaiRx, a revolutionary pharmacy benefit management (PBM) solution targeting the $150 billion TPA market. The program, set to launch in H2 2025, aims to transform traditional PBM services with complete transparency and significant cost reductions.

MarpaiRx's key features include no hidden spreads or markups, real-time prescription optimization, integrated patient assistance programs, and international sourcing options. The platform tackles high specialty drug costs through a multi-pronged approach, including lowest net cost optimization and flexible copay programs. The solution leverages advanced technology for real-time analysis and seamless integration with existing health IT systems.

Marpai (OTCQX: MRAI) released its Q1 2025 financial results, showing mixed performance with significant cost reductions but lower revenue. The company reported net revenues of $5.4 million, down 27% year-over-year, while successfully reducing operating expenses by 33% to $7.7 million. The operating loss improved by 45% to $2.3 million, and net loss decreased by 29% to $3.1 million.

CEO Damien Lamendola highlighted upcoming initiatives including the launch of a Healthcare Management tool with Empara, advancements in MarpaiRx, and the onboarding of new COO Dallas Scrip. The company aims to achieve profitability and positive cash flow by the end of 2025. Marpai ended Q1 with $0.7 million in unrestricted cash, slightly down from the previous year.

Marpai (OTCQX: MRAI), a healthcare technology and Third-Party Administration (TPA) services provider, has appointed Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. Scrip brings extensive experience in scaling private equity and venture capital-owned companies, with expertise in healthcare consumer services, employers, providers, and payor markets.

The strategic hire aims to accelerate Marpai's profitable growth and enhance operational excellence. CEO Damien Lamendola emphasized that Scrip's appointment is crucial for the company's journey towards sustainable growth, citing his proven track record in complex healthcare environments and deep understanding of the TPA landscape.

Marpai Inc. (OTCQX: MRAI), a healthcare technology and Third-Party Administration (TPA) services provider, has scheduled its Q1 2025 earnings conference call for May 15, 2025, at 8:30 a.m. ET. The company will release its first quarter 2025 financial results on Wednesday, May 14, after market close.

The conference call will be accessible via phone (US: 1-646-357-8785 / Toll Free: 1-800-836-8184) and webcast. A replay will be available at the same webcast URL within 2 hours after the call ends and will remain accessible until May 22, 2025. The telephonic replay can be accessed using the code 37963#.

Marpai Inc (OTCQX: MRAI), a technology platform company operating as a national Third-Party Administrator (TPA) for self-funded employer health plans, has announced its participation in the Planet MicroCap Showcase: VEGAS 2025.

The company's presentation is scheduled for Wednesday, April 23, 2025, at 5:30 PM PST. CEO Damien Lamendola and CFO Steve Johnson will lead the presentation and conduct a Q&A session. The event will be held at the Paris Hotel & Casino in Las Vegas, NV.

Investors can attend the live presentation through a webcast and schedule one-on-one meetings with Marpai's management on Thursday, April 24, 2025. The conference is being organized in partnership with MicroCapClub, and registration is required for both the presentation and individual meetings.

Marpai (OTCQX: MRAI), a technology platform company operating as a national Third-Party Administrator (TPA), announced its Q4 and full year 2024 financial results. Q4 2024 showed mixed results with net revenues of $6.6M (6% decrease from Q3), while net loss improved by 67.5% year-over-year to $1.2M.

For Full Year 2024, the company reported net revenues of $28.2M (24.2% decrease YoY), but demonstrated significant improvements in losses. Operating loss decreased by 21.1% to $22.1M, while Adjusted EBITDA loss improved to $9.1M from $20.2M in 2023.

CEO Damien Lamendola highlighted the company's turnaround efforts, announcing plans to introduce PBM-based products in H2 2025. The company aims to achieve profitability in 2025 through continued cost streamlining and innovative services like the Empara Member Engagement Portal.